Dasatinib monohydrate
CAS:863127-77-9
IHS
USDMF No. 23763, USFDA Approved, Stability Studies In Zone IVB
IHS
USDMF No. 23763, USFDA Approved, Stability Studies In Zone IVB
Technical Data
| M. Wt | 506.02 |
| Formula | C22H28ClN7O3S |
| CAS Number | 863127-77-9 |
| PubChem ID | 11540687 |
| InChI Key | XHXFZZNHDVTMLI-UHFFFAOYSA-N |
| Smiles | O.CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1 |
| Documents | USFDA Approved, USDMF available, Stability Studies In Zone IVB. |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Description
Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of , are BCRABL, SRC, Ephrins and GFR.
Synonyms
Dasatinib, Dasatinib hydrate, dasatinib.H2O, Dasatinib (monohydrate), N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide hydrate, dasatinib-monohydrate
Disclaimer
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271 +A13(1)
